SURVIVAL RESULTS OF PATIENTS WITH HIGH-GRADE AND ADVANCED-STAGE ENDOMETRIAL CANCER

Year 2016, Volume: 19 Issue: 4, 139 - 144, 22.05.2018

Alpaslan Kaban , Samet Topuz , Hamdullah Sözen Yavuz Salihoglu

Abstract

Purpose: To evaluate the overall survival and disease-free survival in patients with advanced-stage(FIGO III-IV) and high-grade endometrium

cancer

Patients and Methods: Patients with operated due to endometrial cancer between 2003-2014 and detected FIGO-stage III-IV serous, clearcell,

carcinosarcoma, mixed, grade 3 endometrioid, and undifferentiated histological types according to postoperative pathology report

were selected for the study. Overall survival and disease-free survival times were calculated by Kaplan-Meier survival analysis for each histologic

type.

Results: A total of 85 patients with a median-age of 65(37-86) were included in the study. Of them, 56(65.9%) were stage-III and 29(34.1%)

were stage-IV. The most common histological-type was carcinosarcoma(25.9%, n=22) followed by mixed(22.4%,n=19), serous(17.6%,n=18),

grade 3 endometrioid(17.6% cell (8.2%,n=7) and undifferentiated(4.7%,n=4). During a mean follow-up of 37.1 months(1-148), 63 patients(

74.1%) had recurrence and 60 patients(70.6%) died. The overall survival rate was 29.4%. The highest survival rates were mixed type and

grade 3 endometrioid types(42.1% and 40%) followed by serous(33.3%) and clear-cell(28.6%) and carcinosarcoma(13.6%) and no survival in

undifferentiated type. Median disease-free survival and overall survival were 24 and 49 months for serous type, 28 and 34 months for grade

3 endometrioid type, 15 and 27 months for mixed type, 9 and 18 months for clear cell, 10 and 21 months for carcinosarcoma, 3 and 4 months

for the undifferentiated type

Conclusion: The median disease-free and overall survival of patients were 12 and 28 months, respectively, according to the data of this

study. 74.1% of the patients relapse. The worst prognosis is with undifferentiated types. The prognosis for Grade-3 endometrioid and

mixedtypes seems to be relatively better.

Keywords

serous, clear cell, carcinosarcoma, mixed, grade 3 endometrioid and undifferentiated

İLERİ EVRE YÜKSEK GRADE ENDOMETRİUM KANSERLİ HASTALARDA SAĞKALIM SONUÇLARI

Abstract

Öz

Amaç: İleri evre (FIGO III-IV) yüksek gradeli endometrium kanserli hastaların genel sağkalım ve hastalıksız sağkalımlarını değerlendirmek

Metod: 2003-2014 yılları arasında endometrial kanser nedeniyle opere edilen ve patoloji raporuna göre evre III-IV seröz, berrak hücreli,

karsinosarkom, mikst(endometrioid+no-endometrioid), grade 3 endometrioid ve undiferansiye histolojik tiplere sahip hastalar çalışma için

seçildi. Herbir histolojik tip için Kaplan-Meier sağkalım analizi ile genel sağkalım ve hastalıksız sağkalım süreleri hesaplandı. 

Bulgular: Çalışmaya medyan yaşı 65 (37-86) olan toplam 85 hasta alındı. 56 hasta (%65.9) evre III, 29 hasta (%34.1) evre IV idi. En sık görülen

histolojik tip karsinosarkom (%25.9;n=22), ardından sırayla mixed (%22.4; n=19), serous (%17.6;n=18), grade 3 endometrioid (%17.6;n=15),

berrak hücreli (%8.2;n=7) ve undiferansiye (%4.7; n=4) idi. Ortalama 37.1 aylık (1-148) bir takip süresi boyunca 63 hastada (%74.1) nüks görülmüş,

60 hasta (%70.6) ölmüştü. Genel sağkalım oranı %29.4 idi. En yüksek sağkalım oranları mikst tip ve grade 3 endometrioid tipte (42.1% ve %40)

görüldü, ardından sırayla seröz (%33.3) ve berrak hücreli (%28.6) ve karsinosarkomda (%13.6) idi, undiferansiye tipte sağkalım yoktu (% 0.0). Kaplan-Meier

sağkalım analizine göre, median hastalıksız sağkalım ve genel sağkalım süreleri seröz tip için 24 ve 49 ay, grade 3 endometrioid tip için 28 ve 34 ay, mikst tip

için 15 ve 27 ay, karsinosarkom için 10 ve 21 ay, berrak hücreli için 9 ve 18 ay, undiferansiye tip için 3 ve 4 ay hesaplandı.

Sonuç: İleri evrede tespit edilmiş yüksek gradeli endometrial kanserli hastaların medyan hastalıksız ve genel sağkalım süreleri, bu çalışmanın

verilerine göre 12 ve 28 aydır. Hastaların % 74.1’i nüksetmektedir. En kötü prognoz undiferansiye tiplerdedir. Grade3 endometrioid ve

mikst tiplerde prognoz nispeten daha iyi görünmektedir.

Keywords

seröz, berrak hücreli, karsinosarkom, mikst, grade 3 endometrioid ve undiferansiye

References

• 1. Gottwald L, Pluta P, Piekarski J, Spych M, Hendzel K, Topczewska-Tylinska K, et al. Long-term survival of endometrioid endometrial cancer patients. Arch Med Sci. 2010;6(6):937–44.
• 2. Reynaers EAEM, Ezendam NPM, Pijnenborg JMA. Comparable outcome between endometrioid and nonendometrioid tumors in patients with early-stage highgrade endometrial cancer. J Surg Oncol. 2015;111(6):790– 4.
• 3. Oliva E, Soslow RA. High-Grade Endometrial Carcinomas. Vol. 4, Surgical Pathology Clinics. 2011. p. 199–241.
• 4. Soslow RA. High-grade endometrial carcinomas - strategies for typing. Vol. 62, Histopathology. 2013. p. 89–110.
• 5. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet (London, England). 2005;366(9484):491–505.
• 6. Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120(2 Pt 1):383–97.
• 7. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. In: The Lancet. 2016. p. 1094–108.
• 8. Lee NK. Adjuvant treatment of advanced-stage endometrial cancer. Clin Obstet Gynecol. 2011;54(2):256–65.
• 9. Tangjitgamol S, See HT, Kavanagh J. Adjuvant chemotherapy for endometrial cancer. Int J Gynecol Cancer. 2011;21(5):885–95.
• 10. Cantrell LA, Blank S V., Duska LR. Uterine carcinosarcoma: A review of the literature. Vol. 137, Gynecologic Oncology. 2015. p. 581–8.
• 11. Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA. Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol. 2007;31(11):1653–61.
• 12. Gokce ZK, Turan T, Karalok A, Tasci T, Ureyen I, Ozkaya E, et al. Clinical outcomes of uterine carcinosarcoma: results of 94 patients. Int J Gynecol Cancer. 2015;25(2):279– 87.
• 13. Vaidya AP, Horowitz NS, Oliva E, Halpern EF, Duska LR. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma. Gynecol Oncol. 2006;103(2):684–7.
• 14. Roelofsen T, van Ham MAPC, Wiersma van Tilburg JM, Zomer SF, Bol M, Massuger LFAG, et al. Pure Compared With Mixed Serous Endometrial Carcinoma. Obstet Gynecol. 2012;120(6):1371–81.
• 15. Espinosa I, D’Angelo E, Palacios J, Prat J. Mixed and ambiguous endometrial carcinomas. Am J Surg Pathol. 2016;40(7):972–81.
• 16. Moore KN, Fader AN. Uterine papillary serous carcinoma. Clin Obstet Gynecol. 2011;54(2):278–91.
• 17. Ayeni TA, Bakkum-Gamez JN, Mariani A, McGree ME, Weaver AL, Haddock MG, et al. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol Oncol. 2013;129(3):478– 85.
• 18. Felix AS, Stone RA, Bowser R, Chivukula M, Edwards RP, Weissfeld JL, et al. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers. Int J Gynecol Cancer. 2011;21(5):877–84.
• 19. Hamilton C, Cheung M, Osann K, Chen L, Teng N, Longacre T, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642–6.
• 20. Greggi S, Mangili G, Scaffa C, Scala F, Losito S, Iodice F, et al. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study. Int J Gynecol Cancer. 2011;21(4):661–7.
• 21. Alkushi A, Köbel M, Kalloger SE, Gilks CB. High-Grade Endometrial Carcinoma: Serous and Grade 3 Endometrioid Carcinomas Have Different Immunophenotypes and Outcomes. Int J Gynecol Pathol. 2010;29(4):343–50.